JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
124 hedge funds and large institutions have $343M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
124
Holding in Top 10
2
Calls
$396K
Puts
$1K
Top Buyers
| 1 | +$12.2M | |
| 2 | +$11.4M | |
| 3 | +$7.89M | |
| 4 |
Barclays
London,
United Kingdom
|
+$5.67M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$4.8M |
Top Sellers
| 1 | -$18.2M | |
| 2 | -$15.9M | |
| 3 | -$5.43M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.72M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.6M |